<DOC>
	<DOCNO>NCT01682512</DOCNO>
	<brief_summary>The primary objective trial ( 1 ) To show PK ( Pharmacokinetic ) similarity BI 695500 rituximab . ( 2 ) To establish statistical equivalence efficacy BI 695500 rituximab , patient moderately severely active RA ( Rheumatoid Arthritis ) , base change Disease Activity Score 28 ( DAS28 ) score measure 24 week compare Baseline American College Rheumatology 20 % ( ACR20 ) response rate Week 24 .</brief_summary>
	<brief_title>Efficacy , Pharmacokinetics , Safety BI 695500 Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Inclusion criterion : 1 . Must give write informed consent willing follow protocol . 2 . Male female participant , 18 80 year age , diagnosis moderately severely active RA least 6 month define least six swollen joint ( 66 joint count ) least eight tender joint ( 68 joint count ) Screening Baseline ( Day 1 ) , either erythrocyte sedimentation rate ( ESR ) &gt; 28 mm/hour OR CRP level &gt; 1.0 mg/dL ( normal : &lt; 0.4 mg/dL ) Screening . Patients must inadequate response intolerance conventional DMARD therapy include least one TNF inhibitor . 3 . Positive RF and/or antiCCP antibody . 4 . Current treatment RA outpatient basis : 1 . Must currently receive tolerate oral parenteral MTX therapy dose 1525 mg per week ( dose may low 10 mg per week patient unable tolerate high dose ) least 12 week immediately prior Day 1 . The dose stable least 4 week prior Day 1 Week 24 . After Week 24 administration route change investigator 's discretion . 2 . Patients must willing receive oral folic acid ( least 5 mg/week per local practice ) equivalent entire study ( mandatory comedication MTX treatment ) . 3 . Biologic agent DMARDs ( MTX ) must withdraw least 2 week prior Day 1 , except azathioprine etanercept must withdraw least 4 week prior Day 1 ; abatacept , adalimumab , anakinra , certolizumab , infliximab , golimumab least 8 week prior Day 1 ; tocilizumab least 10 week prior Day 1 . 4 . Leflunomide must withdraw least 8 week prior Day 1 minimum 2 week prior Day 1 11 day standard cholestyramine washout . 5 . If receiving current treatment oral corticosteroid ( intraarticular parenteral ) , dose must exceed 10 mg/day prednisolone equivalent . During 4 week prior Baseline ( Day 1 ) dose must remain stable . 6 . Intraarticular parenteral corticosteroid permit within 6 week prior Baseline Day 1 throughout trial , exception IV administration 100 mg methylprednisolone 30 60 minute prior infusion part trial procedure . 7 . Any concomitant nonsteroidal antiinflammatory drug ( NSAIDs ) must stable least 2 week prior Day 1 . 8 . Patients may take oral hydroxychloroquine provide dose great 400 mg/day chloroquine provide dose great 250 mg/day . These dos must stable minimum 12 week prior Day 1 . The hydroxychloroquine chloroquine treatment need continue stable dose formulation end trial . 5 . For participant reproductive potential ( male female ) , use reliable mean contraception ( e.g. , hormonal contraceptive , patch , intrauterine device , physical barrier ) use throughout trial participation . Females childbearing potential must also agree use acceptable method contraception 12 month follow completion discontinuation trial . Exclusion criterion : 1 . ACR functional Class IV wheelchair/bed bound . 2 . Primary secondary immunodeficiency ( history , currently active ) , include know history human immunodeficiency virus infection . 3 . History positive purify protein derivative test ( positive tuberculosis [ TB ] test ) without treatment TB infection chemoprophylaxis TB exposure . 4 . Positive HIV TB screen . 5 . Known coronary artery disease significant cardiac arrhythmia severe congestive heart failure ( New York Heart Association class III IV ) , interstitial lung disease observe chest Xray . 6 . History IgEmediated nonIgEmediated hypersensitivity know anaphylaxis mouse protein history hypersensitivity antibody therapy . 7 . History cancer include solid tumor , hematologic malignancy , carcinoma situ ( except participant previous resect cured basal squamous cell carcinoma , treat cervical dysplasia , treat situ Grade I cervical cancer within 5 year prior Screening Visit ) . 8 . History pancreatitis current peptic ulcer disease . 9 . Receipt live/attenuated vaccine within 12 week prior Screening Visit . 10 . Any condition treatment ( include biologic therapy ) , opinion investigator , may place patient unacceptable risk trial . 11 . Pregnancy breast feed . 12 . History , current , inflammatory joint disease RA ( e.g. , gout , reactive arthritis , psoriatic arthritis , seronegative spondyloarthropathy , Lyme disease ) systemic autoimmune disorder ( e.g. , systemic lupus erythematosus , inflammatory bowel disease , pulmonary fibrosis , Feltys syndrome , scleroderma , inflammatory myopathy , mixed connective tissue disease , overlap syndrome ) . 13 . Diagnosis juvenile idiopathic arthritis , also know juvenile RA , and/or RA age 16 . 14 . Any surgical procedure , include bone/joint surgery/synovectomy ( include joint fusion replacement ) within 12 week prior Screening Visit plan within 24 week Screening Visit . 15 . Lack peripheral venous access . 16 . Evidence significant uncontrolled concomitant disease , limited , nervous system , renal , hepatic , endocrine , gastrointestinal disorder , investigator 's opinion , would preclude patient participation . 17 . Known concurrent viral hepatitis know positivity HBeag , HBV DNA , HBV DNA polymerase , HCVRNA , anti HCV antibody . 18 . Known active infection kind ( exclude fungal infection nail bed ) , major episode infection require hospitalization treatment IV antiinfectives within 4 week Screening Visit completion oral antiinfectives within 2 week Screening Visit . 19 . History deep space/tissue infection ( e.g. , fasciitis , abscess , osteomyelitis ) within 52 week Screening Visit . 20 . History serious infection opportunistic infection last 2 year . 21 . Any neurological ( congenital acquire ) , vascular systemic disorder might affect efficacy assessment , particular , joint pain swelling ( e.g. , Parkinson 's disease , cerebral palsy , diabetic neuropathy ) . 22 . Currently active alcohol drug abuse history alcohol drug abuse ( determine investigator ) within 52 week Screening Visit . 23 . Treatment IV Gamma Globulin Prosorba® Column within 6 month Screening Visit . 24 . Treatment IV intramuscular corticosteroid . 25 . Previous treatment B cell modulate cell deplete therapy . 26 . Intolerance contraindication IV glucocorticoid . 27 . AST ALT &gt; 3 time ULN . 28 . Hemoglobin &lt; 8.0 g/dL . 29 . Levels IgG &lt; 5.0 g/L . 30 . Absolute neutrophil count &lt; 1500/µL . 31 . Platelet count &lt; 75000/µL . 32 . Participation previous clinical trial within 12 week Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>